Gary Brecka

It's no longer in a black box of the insurance company and the pharmacy benefit manager.

Right.

So there's a lot to do.

So there's so much to do.

I think for folks that are in my industry, you know, we see, you know, when we had our clinic, we had a large population of patients that were going outside the United States for a lot of treatments, you know, mainly stem cells, exosomes.

So they're having to go to third world countries.

And some of these facilities are very, you know, they're U.S.

doctors there and they're

well-run facilities, but people are still going to Medellin, Tijuana, Panama, Costa Rica, and I'm not throwing shade in any of those countries, Nicaragua, to get therapies that are helping them regenerate their joints, that are giving them

for neurodegenerative disorders that are helping them repair tissues, amniotic stem cell injections for type one diabetes.

And is there, let's call it the stem cell biologic exosome space, is there a view that we might be able to bring this back in under the FDA's purvey?

in a reasonable timeframe so people can have access to safe evidence-backed therapies that include some of these biologics like stem cells.

Where do you see that lane widening?

Yeah, we've got to modernize.

And so if people are all leaving the United States for a therapy that has good data to support it, what are we doing?

We're just blocking people from access to therapies that may have good data.

If a therapy has good data, we'd like to see it.

And we've got to get over these sort of prejudices that exist sometimes.

among the scientists at the FDA, but larger prejudices that the medical establishment has had.

And I'm being honest because I was a part of the medical establishment in all of its academic regalia, at all the top, I trained at a bunch of the top institutions, Harvard, Johns Hopkins, Georgetown.